Although GEM-based chemotherapies are currently the standard of care for the treatment of advanced pancreatic cancer, its efficacy is limited because pancreatic cancer cells are often resistant to GEM through a mechanism that involves NF-κB activation. This evidence concerns the gene NFKB1 and familial pancreatic carcinoma.